Health TrialsbyHealthPanel

Prevalence and Clinical Significance of Hematological Abnormalities in Patients With Clinically Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Case-Control Study

ConditionMASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAssiut University

About this trial

this study aims to investigate the prevalence of hematological abnormalities among patients with clinically diagnosed MASLD, evaluate their clinical correlates, and examine their association with non-invasive fibrosis scores. The findings may improve risk stratification and facilitate early identification of patients who require closer monitoring or further hepatological assessment.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults aged ≥18 years.

Patients with a clinical diagnosis of MASLD based on fibroscan records.

Availability of complete blood count (CBC) data.

Availability of relevant demographic and clinical information.

Disqualifiers

Age below 18 years.

Alcoholic liver disease.

Viral hepatitis.

Autoimmune liver diseases.

Trial population

El-Raghy Hospital patients

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

120 Participants
are grouped into 1 trial group
Group A: MASLD patients

Trial outcomes

Primary outcomes

1

• To determine the difference in prevalence of thrombocytopenia between cases and controls

To determine the difference in prevalence of thrombocytopenia between patients with clinically diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) and control participants.

Time frame
Baseline (at the index CBC assessment corresponding to MASLD diagnosis for cases and the corresponding index CBC assessment for controls).

Secondary outcomes

1

· To determine the difference in prevalence of other hematological abnormalities, including anemia, neutropenia, thrombocytosis, and any complete blood count (CBC) abnormality

Time frame
Baseline (at the index CBC assessment corresponding to MASLD diagnosis for cases and the corresponding index CBC assessment for controls)
2

· To assess the association between hematological abnormalities and demographic and clinical characteristics

Time frame
Baseline (at the index assessment corresponding to the CBC assessment for cases and the corresponding index assessment for controls).
3

· To evaluate the relationship between CBC abnormalities and non-invasive liver fibrosis scores, including the Fibrosis-4 Index (FIB-4) and the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI)

Time frame
Baseline (using laboratory data corresponding to the index CBC assessment for cases and the corresponding index assessment for controls).

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: